CENTER VALLEY, Pa., May 12,
2021 /PRNewswire/ -- Olympus announced today
the market launch of the FDA 510(k)-cleared BF-UC190F endobronchial
ultrasound (EBUS) bronchoscope, the newest addition to its
robust EBUS portfolio of devices for minimally invasive lung cancer
diagnosis and staging via needle biopsy. Today, more than 1,600
clinical cases using the Olympus EBUS solution prove that EBUS-TBNA
(transbronchial needle aspiration) is an effective biopsy solution,
providing higher diagnostic yield with greater sensitivity and
specificity in lymph nodes ≥5 mm. According to the American College
of Chest Physicians (ACCP), correctly staging lung cancer is
critical, because the treatment options and prognosis differ
significantly by stage, and the ACCP recommends EBUS-TBNA as the
optimal first test rather than surgery for mediastinal
staging.i
For more information about the BF-UC190F, please visit
https://medical.olympusamerica.com/products/bf-uc190f
In conjunction with the versatile Olympus ViziShot EBUS-TBNA
needle portfolio, the BF-UC190F allows physicians to access and
sample difficult-to-reach targets such as lymph nodes in the
mediastinum (4L) and hilum (10R). Key design features of the
BF-UC190F that enable improved access and sampling include:
- Powerful Scope Angulation: With an increase in
angulation from 120 degrees to 160 degrees, this new EBUS-TBNA
bronchoscope has the flexibility to ensure the correct positioning
of the scope tip relative to the target.
- Compact Distal Tip: With a distal diameter of 6.6mm, the
BF-UC190F is smoother to insert and easier to maneuver within the
lung.
- Steeper Puncture Angle: A more perpendicular needle
orientation allows for smoother penetration between cartilage rings
and other critical anatomy.
- Enhanced Endoscopic View: With a decreased forward
oblique angle of 20 degrees and higher resolution images, the
BF-UC190F increases the field of view and improves visualization of
the anatomy for more precise airway navigation and abnormality
detection.
"When reaching a lymph node to obtain a tissue sample, it is
critical to be able to achieve the correct positioning within the
lung. In my study of this new EBUS-TBNA bronchoscope, I found that
the sharper puncture angle greatly improves the ability of
physicians to puncture the lymph node precisely without needing to
use more force or to alter technique," said Kazuhiro Yasufuku, MD, PhD, FRCSC, Professor and
Chair of Thoracic Surgery at the University of
Toronto and the William Coco Chair in Surgical Innovation
for Lung Cancer at the University Health Network. "The BF-UC190F
bronchoscope is a valuable advancement in the use of EBUS-TBNA for
the diagnosis and staging of lung cancer."
"We are very excited to launch this next-generation EBUS
bronchoscope, which will further the ability of physicians to
biopsy mediastinal and hilar lymph nodes through a minimally
invasive procedure," said Lynn Ray,
Vice President and General Manager of the Global Respiratory
Business Unit for Olympus Corporation. "Our goal as a company is to
develop leading-edge technology that helps physicians diagnose
disease earlier and more accurately, which can save lives."
According to the American Cancer Society, lung cancer is the
second most common cancer and the leading cause of cancer death in
the US — in 2021, an estimated 235,760 people were diagnosed with
lung cancer, and 131,880 people died of the
disease.ii While lung cancer has an overall
five-year survival rate of only 20 percent, lung cancer detected
and treated at an early stage increases the chance of survival
beyond five years.iii In March
2021, the U.S. Preventive Services Task Force (USPSTF)
announced new recommendations for annual lung cancer screening
using low-dose computed tomography (LDCT) for people at high risk
for lung cancer, lowering the screening age to 50 and lowering the
smoking threshold to 20 pack years, or those who currently smoke or
have quit within the past 15 years.iv
About Olympus
As a leading medical technology
company, Olympus uses innovative capabilities in medical
technology, therapeutic intervention, and precision manufacturing
to help healthcare professionals deliver diagnostic, therapeutic,
and minimally invasive procedures to improve clinical outcomes,
reduce overall costs, and enhance the quality of life for patients.
Olympus' Medical portfolio includes endoscopes, laparoscopes, and
video imaging systems, as well as surgical energy devices, system
integration solutions, medical services, and a wide range of
endotherapy instruments. For more information, visit
www.medical.olympusamerica.com.
|
|
|
i Frank C. Detterbeck FC, Postmus,
PE, Tanoue, LT. Diagnosis and Management of Lung Cancer, 3rd
ed: American College of Chest Physicians Evidence-Based Clinical
Practice Guidelines. CHEST. 2013; 143(5).
|
ii Key Statistics for Lung Cancer.
Cancer.org.
https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html
Last revised January 12, 2021. Accessed May 7, 2021.
|
iii Non-Small Cell Lung Cancer
Treatment (PDQ®)–Health Professional Version. National Cancer
Institute. Updated November 18, 2020. Accessed January 15,
2021. https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq
|
iv Lung Cancer: Screening.
USpreventiveservicestaskforce.org. Published March 9,2021. Accessed
April 21, 2021.
https://uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening.
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/olympus-announces-new-endobronchial-ultrasound-ebus-bronchoscope-301289717.html
SOURCE Olympus Medical Systems Group